Patents by Inventor Paul John Whiting

Paul John Whiting has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS
    Publication number: 20150159134
    Abstract: The invention relates to a method for producing retinal pigment epithelial cells.
    Type: Application
    Filed: December 10, 2014
    Publication date: June 11, 2015
    Applicant: PFIZER LIMITED
    Inventors: PARUL CHOUDHARY, BEATA SURMACZ-CORDLE, HEATHER DAWN ELLEN FOX, PAUL JOHN WHITING
  • Delta subunit of human GABAA receptor
    Patent number: 7157249
    Abstract: The present invention relates to the cloning of novel cDNA sequences encoding the ?4 and ? receptor subunits of the human GABA A receptor; to stably co-transfected eukaryotic cell lines capable of expressing a human GABAA receptor, which receptor comprises at least one of the novel ?4 and ? receptor subunits; and to the use of such cell lines in screening for and designing medicaments which act upon the human GAGAA receptor.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: January 2, 2007
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Beatrice Le Bourdelles, Paul John Whiting
  • Selective anesthetic agents and methods of identifying the same
    Publication number: 20050014834
    Abstract: The present invention relates to the use of GABAA receptor ?3 selective anesthetic agents for the manufacture of medicaments for providing anesthesia; to transgenic animals of use in the testing of such agents; and to methods for screening for GABAA receptor ?3 selective anesthetic agents.
    Type: Application
    Filed: December 11, 2002
    Publication date: January 20, 2005
    Inventors: David Reynolds, Thomas Rosahl, Keith Wafford, Paul John Whiting
  • Human theta subunit of the GABAa receptor
    Patent number: 6555341
    Abstract: This invention concerns the cloning of a novel cDNA sequence encoding a particular subunit of the human GABAA receptor. In addition, the invention relates to a stable cell line capable of expressing said cDNA and to the use of the cell line in a screening technique for the design and development of subtype-specific medicaments.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: April 29, 2003
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Timothy Peter Bonnert, Paul John Whiting
  • Delta subunit of human GABAA receptor
    Publication number: 20030013158
    Abstract: The present invention relates to the cloning of novel cDNA sequences encoding the &agr;4 and &dgr; receptor subunits of the human GABAA receptor; to stably co-transfected eukaryotic cell lines capable of expressing a human GABAA receptor, which receptor comprises at least one of the novel &agr;4 and &dgr; receptor subunits; and to the use of such cell lines in screening for and designing medicaments which act upon the human GAGAA receptor.
    Type: Application
    Filed: August 2, 2002
    Publication date: January 16, 2003
    Applicant: Merck Sharp & Dohme, Ltd.
    Inventors: Beatrice Le Bourdelles, Paul John Whiting
  • Human &agr;4 receptor subunit of the GABA-A receptor
    Patent number: 6455276
    Abstract: The present invention provides nucleotide sequences encoding the &agr;4 and &dgr; subunits of the human GABAA receptor, preparations of &agr;4 and &dgr; receptor subunit proteins, preparations of receptors including &agr;4 or &dgr; polypeptides, expression vectors including the nucleotide sequences, stably co-transfected eukaryotic cells and methods of their preparation and methods of screening for and designing medicaments which act upon the GABAA receptor.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: September 24, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Beatrice Le Bourdelles, Paul John Whiting
  • Antipsychotic use of triazolo-pyridazine derivatives
    Patent number: 6174886
    Abstract: A class of substituted or 7,8-ring fused 1,2,4-triazolo[4,3-b]pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position and a substituted alkoxy moiety at the 6-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders including schizophrenia.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: January 16, 2001
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Jose Luis Castro Pineiro, Ruth McKernan, Paul John Whiting
  • Human NMDA R2A receptor subunit and isoforms of the human NMDA-R1 receptor subunit and encoding cDNAs
    Patent number: 6130058
    Abstract: The present invention relates to a stably co-transfected eukaryotic cell line that expresses an N-methyl-D-aspartate (NMDA) receptor, particularly a human NMDA receptor, which receptor comprises at least one R1 subunit isoform, or at least one R1 subunit isoform and one or two R2 subunits. Additionally, the cell line can be used to design and develop NMDA receptor subtype-selective compounds. The invention also relates to cloning of novel cDNA sequences encoding the human NMDAR 2A subunit and various isoforms of the human NMDA R1 subunit.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: October 10, 2000
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Beatrice Le Bourdelles, Janice Ann Myers, Paul John Whiting
  • Stably human transfected rodent fibroblast cell line expressing human GABA-A recepotors, and cloned human GABA-A receptor subunit CDNA sequences
    Patent number: 5719057
    Abstract: The present invention relates to a stably co-transfected eukaryotic cell line capable of expressing a GABA-A receptor, particularly a human GABA-A receptor, which receptor comprises at least one alpha, one beta and one gamma subunit; to the cloning of novel cDNA sequences encoding the .alpha.-2, .alpha.-3, .alpha.-5, .alpha.-6 and .beta.-2 subunits of the human GABA-A receptor; and to the use of the cell line in designing and developing GABA-A receptor subtype-selective medicaments.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: February 17, 1998
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Karen Louise Hadingham, Beatrice le Bourdelles, Paul John Whiting, Peter Baxter Wingrove
  • cDNA cloning of inositol monophosphatase
    Patent number: 5710015
    Abstract: The present invention relates to the cloning of novel cDNA sequences encoding human and rat inositol monophosphatase (IMP); to the preparation of IMP enzyme by incorporation of the cDNAs into an expression vector and the expression thereof in recombinant host cells; and to the use of the enzyme thereby obtained in designing and developing medicaments which are inhibitors of human or rat IMP.
    Type: Grant
    Filed: January 18, 1995
    Date of Patent: January 20, 1998
    Assignee: Merck, Sharp & Dohme, Ltd.
    Inventors: George McAllister, Paul John Whiting
  • Stably transfected rodent fibroblast cell lines expressing human GABA-.sub.A -receptors
    Patent number: 5652100
    Abstract: The present invention relates to stably co-transfected eukaryotic cell lines capable of expressing a recombinant GABA.sub.A receptor, particularly a recombinant human GABA.sub.A receptor, which comprises at least one alpha, one beta and one gamma subunit; and to the use of the cell line and/or membrane preparation in selecting compounds and designing medicaments which interact with the respective human recombinant GABA.sub.A receptor.
    Type: Grant
    Filed: November 17, 1994
    Date of Patent: July 29, 1997
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Karen Hadingham, Paul John Whiting